Preoperative splenic area as a prognostic biomarker of early-stage non-small cell lung cancer

被引:0
|
作者
Liu, Mengmei [1 ]
Yan, Guanghong [1 ]
Li, Yanli [2 ]
You, Ruiming [2 ]
Liu, Lizhu [2 ]
Zhang, Dafu [2 ]
Yang, Guangjun [2 ]
Dong, Xingxiang [2 ]
Ding, Yingying [2 ]
Yan, Shan [3 ]
You, Dingyun [1 ,2 ]
Li, Zhenhui [2 ]
机构
[1] Kunming Med Univ, Yunnan Prov Key Lab Publ Hlth & Biosafety, 1168 West Chunrong Rd, Kunming 650500, Yunnan, Peoples R China
[2] Kunming Med Univ, Yunnan Canc Hosp, Affiliated Hosp 3, Yunnan Canc Ctr, Kunming 650118, Peoples R China
[3] Kunming Med Univ, Inst Biomed Engn, 1168 West Chunrong Rd, Kunming 650500, Yunnan, Peoples R China
关键词
NSCLC; Modality; CT; Overall survival; Splenic area; SUPPRESSOR-CELLS; LOCAL RECURRENCE; SURGERY; SPLEEN;
D O I
10.1186/s40644-023-00640-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundThe correlation between the preoperative splenic area measured on CT scans and the overall survival (OS) of early-stage non-small cell lung cancer (NSCLC) patients remains unclear.MethodsA retrospective discovery cohort and validation cohort consisting of consecutive NSCLC patients who underwent resection and preoperative CT scans were created. The patients were divided into two groups based on the measurement of their preoperative splenic area: normal and abnormal. The Cox proportional hazard model was used to analyse the correlation between splenic area and OS.ResultsThe discovery and validation cohorts included 2532 patients (1374 (54.27%) males; median (IQR) age 59 (52-66) years) and 608 patients (403 (66.28%) males; age 69 (62-76) years), respectively. Patients with a normal splenic area had a 6% higher 5-year OS (n = 727 (80%)) than patients with an abnormal splenic area (n = 1805 (74%)) (p = 0.007) in the discovery cohort. A similar result was obtained in the validation cohort. In the univariable analysis, the OS hazard ratios (HRs) for the patients with abnormal splenic areas were 1.32 (95% confidence interval (CI): 1.08, 1.61) in the discovery cohort and 1.59 (95% CI: 1.01, 2.50) in the validation cohort. Multivariable analysis demonstrated that abnormal splenic area was independent of shorter OS in the discovery (HR: 1.32, 95% CI: 1.08, 1.63) and validation cohorts (HR: 1.84, 95% CI: 1.12, 3.02).ConclusionPreoperative CT measurements of the splenic area serve as a prognostic indicator for early-stage NSCLC patients, offering a novel metric with potential implications for personalized therapeutic strategies in top-tier oncology research.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Nonintubated thoracoscopic surgery for early-stage non-small cell lung cancer
    Wan-Ting Hung
    Ya-Jung Cheng
    Jin-Shing Chen
    [J]. General Thoracic and Cardiovascular Surgery, 2020, 68 : 733 - 739
  • [32] Immune checkpoint inhibition in early-stage non-small cell lung cancer
    Cuppens, Kristof
    Du Pont, Bert
    Knegjens, Joost
    Maes, Brigitte
    Baas, Paul
    [J]. LUNG CANCER, 2024, 193
  • [33] Health behaviors of early-stage non-small cell lung cancer survivors
    Paul Krebs
    Elliot J. Coups
    Marc B. Feinstein
    Jack E. Burkhalter
    Richard M. Steingart
    Amy Logue
    Bernard J. Park
    Jamie S. Ostroff
    [J]. Journal of Cancer Survivorship, 2012, 6 : 37 - 44
  • [34] Evaluation of outcome by race in early-stage non-small cell lung cancer
    Jahanzeb, M
    Virgo, KS
    McKirgan, LW
    Johnson, FE
    [J]. ONCOLOGY REPORTS, 1997, 4 (01) : 183 - 186
  • [35] Features of fatigue in patients with early-stage non-small cell lung cancer
    Huang, Xianping
    Zhou, Weihe
    Zhang, Yuefeng
    [J]. JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2015, 20 (03): : 268 - 272
  • [36] Immunotherapy for early-stage non-small cell lung cancer: A system review
    Gao, Jingyi
    Zhang, Chao
    Wei, Zhigang
    Ye, Xin
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (04) : 849 - 865
  • [37] Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small Cell Lung Cancer
    Shukla, Nikhil
    Hanna, Nasser
    [J]. LUNG CANCER-TARGETS AND THERAPY, 2021, 12 : 51 - 60
  • [38] Health behaviors of early-stage non-small cell lung cancer survivors
    Krebs, Paul
    Coups, Elliot J.
    Feinstein, Marc B.
    Burkhalter, Jack E.
    Steingart, Richard M.
    Logue, Amy
    Park, Bernard J.
    Ostroff, Jamie S.
    [J]. JOURNAL OF CANCER SURVIVORSHIP, 2012, 6 (01) : 37 - 44
  • [39] Is Brain MRI Unnecessary for Early-Stage Non-Small Cell Lung Cancer?
    Bizzi, Alberto
    Pascuzzo, Riccardo
    [J]. RADIOLOGY, 2022, 303 (03) : 644 - 645
  • [40] Adjuvant Chemotherapy in Patients With Early-Stage Non-Small Cell Lung Cancer
    Inamura, Kentaro
    [J]. JAMA ONCOLOGY, 2021, 7 (04) : 637 - 638